Eylea
Eylea sales jump helps boost Regeneron in Q2 results
August 5, 2016Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results
Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …
Nice says Bayer’s Eylea not recommended as first-line treatment in draft recommendation
June 10, 2016Medical Communications, Research and Development Bayer, Eylea, NICE, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) in a provisional guidance said Bayer’s (ETR: BAYN) Eylea (aflibercept) is …
Bayer’s earnings beat estimates as blockbusters shine
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales
Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …
Bayer, Regeneron’s Eylea gets additional EU indication
November 2, 2015Research and Development, Sales and Marketing Bayer, Eylea, Regeneron
The European Commission has granted a fifth indication to Bayer and Regeneron’s eye drug Eylea (aflibercept injection), which is now …
Bayer’s complaint over ‘misleading’ Novartis eye drug claims upheld
August 14, 2015Medical Communications Bayer, Eylea, Lucentis, Novartis, PMCPA, code of conduct
The industry’s code of conduct regulator has ruled in favour of Bayer in a dispute claims made by Novartis when …
Bayer’s Eylea approved in Japan
June 29, 2015Sales and Marketing Eylea, Japan, aflibercept. bayer
German firm Bayer has been shown the green light by the Japanese Ministry of Health, Labour and Welfare to market …
NICE signs-off Roche’s Gazyvaro for leukaemia
June 2, 2015Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia
NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …
Profits fall at Bayer but new drugs see growth
May 1, 2015Sales and Marketing Bayer, Eliquis, Eylea, Renegeron, Xarelto, apixaban
Bayer’s pharmaceutical revenues have continued their upward trajectory in the first quarter of 2015 thanks to new products, although this …
Bayer and Regeneron eye drug gains another indication
March 26, 2015Sales and Marketing Bayer, Eylea, FDA, Japan, Lucentis, MRI, Regeneron, aflibercept
Bayer and Regeneron’s Eylea has added to a growing list of indications with its new approval to treat a type …
New EU indication for Bayer and Regeneron eye drug
February 27, 2015Sales and Marketing Bayer, European Commission, Eylea, aflibercept
Bayer and Regeneron’s Eylea is now indicated for every type of the eye disease retinal vein occlusion (RVO) thanks to …
New drugs give Bayer record sales
February 26, 2015Sales and Marketing Bayer, Eylea, Radium-223 chloride, Stivarga, Xarelto, adempas, aflibercept, dekkers, german, regorafenib, riociguat, xofigo
Bayer has reported strong financial results for 2014 driven primary by sales of new medicines, although controversy surrounding its anti-clotting …
AstraZeneca diabetes drug approved for use in Scotland
November 11, 2014Sales and Marketing Afinitor, AstraZeneca, Eylea, Onglyza, Perjeta, SMC, diabetes, type 2
The Scottish Medicines Consortium (SMC) has shown AstraZeneca’s Onglyza (saxagliptin) the green light to be used with insulin in patients …
Xarelto lift for Bayer
March 3, 2014Manufacturing and Production, Sales and Marketing Bayer, Eylea, Stivarga, Xarelto, blood thinner, xofigo
Bayer Group says sales of its blood thinner Xarelto will be higher than it had predicted, with peak annual sales …
Bayer and Regeneron to co-develop wet AMD antibody
January 14, 2014Research and Development, Sales and Marketing Bayer, Eylea, Regeneron, pdgfr-beta, wet AMD
Bayer and Regeneron are co-developing an antibody to the Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) as a combination therapy …
Bayer submits Eylea in EU for DME
November 8, 2013Sales and Marketing Bayer, DME, EMA, Eylea, FDA
Bayer HealthCare is seeking to extend the licence of its VEGF Trap-Eye, which is already marketed as Eylea in various …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
